SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review.

Diabetes Ther · 2017 · PMC5688986 · PMID 29076040

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The individual components of 3P-MACE in the EMPA-REG trial showed a trend for non-inferiority (HR either side of 1.0), except for CV deaths (HR 0.62, 95% CI 0.49–0.77), which was the major driver for 3P-MACE reduction.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.